Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of open-angle glaucoma (OAG) or ocular hypertension (OHT) in at least one eye.~* Non-study eye: Intraocular pressure (IOP) able to be controlled with no pharmacologic therapy or on the study medicine alone.~* Willing to discontinue the use of all other ocular hypotensive medications prior to receiving study medication and for the entire course of the study.~* Able to follow instructions, self instill study article, and attend all study visits.~* Best-corrected Snellen visual acuity of 20/200 or better in each eye.~* Sign Ethics Committee reviewed and approved informed consent form.~* Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Known medical history of allergy, hypersensitivity or poor tolerance to any component of the preparations used in this study.~* Any abnormality preventing applanation tonometry in either eye.~* Dry eye previously or currently being treated with punctal plugs, punctal cautery, Restasis®, or topical ocular corticosteroids.~* Concurrent infectious/noninfectious conjunctivitis, keratitis or uveitis in either eye.~* Intraocular conventional or laser surgery \>3 months prior to consent.~* Risk of visual field or visual acuity worsening as a consequence of participation in the study, in the investigator's best judgment.~* Progressive retinal or optic nerve disease from any cause.~* Use of any systemic medications known to affect IOP which have not been on a stable course for at least 7 days prior to Screening or an anticipated change in dosage during the course of the study.~* Any clinically significant, serious, or severe medical condition.~* Women of childbearing potential who are pregnant, lactating, or not using reliable means of birth control.~* Participation in any other study within 30 days prior to Screening.~* Use of any systemic (oral), injectable or topical steroids.~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TRAVATAN, then LUMIGAN (Type: OTHER): Travoprost 0.004% ophthalmic solution (TRAVATAN), 1 drop to the study eye once daily every evening at 8:00 pm for 6 weeks, followed by bimatoprost 0.01% ophthalmic solution (LUMIGAN), same dose, same duration, as randomized, for a total duration of 12 weeks
- LUMIGAN, then TRAVATAN (Type: OTHER): Bimatoprost 0.01% ophthalmic solution (LUMIGAN), 1 drop to the study eye once daily every evening at 8:00 pm for 6 weeks, followed by travoprost 0.004% ophthalmic solution (TRAVATAN), same dose, same duration, as randomized, for a total duration of 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete